Humanized Chondroitinase ABC Sensitizes Glioblastoma Cells to Temozolomide

Overview

Journal J Gene Med

Specialties Genetics
Molecular Biology

Date 2017 Jan 15

PMID 28087981

Citations 24

Authors

Alena Cristina Jaime-Ramirez

Nina Dmitrieva

Ji Young Yoo

Yeshavanth Banasavadi-Siddegowda

Jianying Zhang

Theresa Relation

Chelsea Bolyard

Jeffrey Wojton

Balveen Kaur

Affiliations

Soon will be listed here.

Abstract

Background: Malignant gliomas (glioblastomas; GBMs) are extremely aggressive and have a median survival of approximately 15 months. Current treatment modalities, which include surgical resection, radiation and chemotherapy, have done little to prolong the lives of GBM patients. Chondroitin sulfate proteoglycans (CSPG) are critical for cell-cell and cell-extracellular matrix (ECM) interactions and are implicated in glioma growth and invasion. Chondroitinase (Chase) ABC is a bacterial enzyme that cleaves chondroitin sulfate disaccharide chains from CSPGs in the tumor ECM. Wild-type Chase ABC has limited stability and/or activity in mammalian cells; therefore, we created a mutant humanized version (Chase M) with enhanced function in mammalian cells.

Methods: We hypothesized that disruption of cell-cell and cell-ECM interactions by ChaseM and temozolomide (TMZ) will enhance the chemotherapeutic availability and sensitivity of glioma cells.

Results: Utilizing primary patient-derived neurospheres, we found that ChaseM decreases glioma neurosphere aggregation in vitro. Furthermore, an oncolytic HSV-1 virus expressing secreted ChaseM (OV-ChaseM) enhanced viral spread and glioma cell killing compared to OV-Control, in vitro. OV-ChaseM plus TMZ combinatorial treatment resulted in a significant synergistic enhancement of glioma cell killing accompanied by an increase in apoptotic cell death. Intracellular flow cytometric analysis revealed a significant reduction in the phosphorylation of the pro-survival AKT protein following OV-ChaseM plus TMZ treatment. Lastly, in nude mice bearing intracranial GBM30 glioma xenografts, intratumoral OV-ChaseM plus TMZ (10 mg/kg by oral gavage) combination therapy resulted in a significant (p < 0.02) enhancement of survival compared to each individual treatment alone.

Conclusions: These data reveal that OV-ChaseM enhances glioma cell viral susceptibility and sensitivity to TMZ.

Citing Articles

Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses.

Soko G, Kosgei B, Meena S, Ng Y, Liang H, Zhang B Front Immunol. 2025; 15():1535647.

PMID: 39845957 PMC: 11751056. DOI: 10.3389/fimmu.2024.1535647.

Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data.

Smerdi D, Moutafi M, Kotsantis I, Stavrinou L, Psyrri A Life (Basel). 2024; 14(6).

PMID: 38929657 PMC: 11204771. DOI: 10.3390/life14060673.

Patient-derived organoids recapitulate glioma-intrinsic immune program and progenitor populations of glioblastoma.

Watanabe F, Hollingsworth E, Bartley J, Wisehart L, Desai R, Hartlaub A PNAS Nexus. 2024; 3(2):pgae051.

PMID: 38384384 PMC: 10879747. DOI: 10.1093/pnasnexus/pgae051.

Oncolytic Increases Autophagy in Multiple Myeloma.

Yesilaltay A, Muz D, Erdal B Turk J Haematol. 2024; 41(1):16-25.

PMID: 38258554 PMC: 10918390. DOI: 10.4274/tjh.galenos.2024.2023.0403.

CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.

Lin Y, Chu Y, Liao W, Chen C, Hsiao W, Ho Y Am J Cancer Res. 2023; 13(7):2998-3012.

PMID: 37559985 PMC: 10408464.

References

Wade A, Robinson A, Engler J, Petritsch C, James C, Phillips J . Proteoglycans and their roles in brain cancer. FEBS J. 2013; 280(10):2399-417. PMC: 3644380. DOI: 10.1111/febs.12109. View

Westhoff M, Zhou S, Bachem M, Debatin K, Fulda S . Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene. 2008; 27(39):5169-81. DOI: 10.1038/onc.2008.148. View

Wu L, Yang L, Xiong Y, Guo H, Shen X, Cheng Z . Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells. Tumour Biol. 2014; 35(12):12327-37. DOI: 10.1007/s13277-014-2545-1. View

Asimakopoulou A, Theocharis A, N Tzanakakis G, Karamanos N . The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo. 2008; 22(3):385-9. View

Chekenya M, Krakstad C, Svendsen A, Netland I, Staalesen V, Tysnes B . The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 2008; 27(39):5182-94. PMC: 2832310. DOI: 10.1038/onc.2008.157. View

Fthenou E, Zong F, Zafiropoulos A, Dobra K, Hjerpe A, N Tzanakakis G . Chondroitin sulfate A regulates fibrosarcoma cell adhesion, motility and migration through JNK and tyrosine kinase signaling pathways. In Vivo. 2009; 23(1):69-76. View

Zhao H, Zhang C, Hou G, Song J . MicroRNA-H4-5p encoded by HSV-1 latency-associated transcript promotes cell proliferation, invasion and cell cycle progression via p16-mediated PI3K-Akt signaling pathway in SHSY5Y cells. Int J Clin Exp Med. 2015; 8(5):7526-34. PMC: 4509241. View

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

Yang Y, Sun C, Wilhelm M, Fox L, Zhu J, Kaufman L . Influence of chondroitin sulfate and hyaluronic acid on structure, mechanical properties, and glioma invasion of collagen I gels. Biomaterials. 2011; 32(31):7932-40. PMC: 3159748. DOI: 10.1016/j.biomaterials.2011.07.018. View

10.

Ulbricht U, Eckerich C, Fillbrandt R, Westphal M, Lamszus K . RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo. J Neurochem. 2006; 98(5):1497-506. DOI: 10.1111/j.1471-4159.2006.04022.x. View

11.

Hayes G, Chiu R, Carpenito C, Dougherty S, Dougherty G . Identification of sequence motifs responsible for the adhesive interaction between exon v10-containing CD44 isoforms. J Biol Chem. 2002; 277(52):50529-34. DOI: 10.1074/jbc.M206719200. View

12.

Engelman J . Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9(8):550-62. DOI: 10.1038/nrc2664. View

13.

Theocharis A, Skandalis S, N Tzanakakis G, Karamanos N . Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010; 277(19):3904-23. DOI: 10.1111/j.1742-4658.2010.07800.x. View

14.

Mihaliak A, Gilbert C, Li L, Daou M, Moser R, Reeves A . Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett. 2010; 296(2):168-77. PMC: 2914162. DOI: 10.1016/j.canlet.2010.04.005. View

15.

Haylock-Jacobs S, Keough M, Lau L, Yong V . Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system. Autoimmun Rev. 2011; 10(12):766-72. DOI: 10.1016/j.autrev.2011.05.019. View

16.

Dmitrieva N, Yu L, Viapiano M, Cripe T, Chiocca E, Glorioso J . Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res. 2010; 17(6):1362-72. PMC: 3140790. DOI: 10.1158/1078-0432.CCR-10-2213. View

17.

Andtbacka R, Kaufman H, Collichio F, Amatruda T, Senzer N, Chesney J . Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015; 33(25):2780-8. DOI: 10.1200/JCO.2014.58.3377. View

18.

Lobao-Soares B, Alvarez-Silva M, de Aguiar C, Nicolau M, Trentin A . Undersulfation of glycosaminoglycans induced by sodium chlorate treatment affects the progression of C6 rat glioma, in-vivo. Brain Res. 2006; 1131(1):29-36. DOI: 10.1016/j.brainres.2006.11.014. View

19.

Santini M, Rainaldi G, Indovina P . Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit Rev Oncol Hematol. 2000; 36(2-3):75-87. DOI: 10.1016/s1040-8428(00)00078-0. View

20.

Killock D . Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol. 2015; 12(8):438. DOI: 10.1038/nrclinonc.2015.106. View